This 2011 narrative review by Bonewald synthesizes a decade of molecular and transgenic evidence redefining the osteocyte as an active orchestrator of bone remodeling and a bona fide endocrine cell. It asks: what do osteocytes actually do, and why does their death matter clinically? The paper covers mechanosensation, sclerostin/Wnt signaling, perilacunar remodeling, phosphate metabolism via FGF-23, and the consequences of osteocyte death.
Two drugs you prescribe regularly — bisphosphonates and romosozumab. Work partly through osteocyte pathways, and understanding this makes their mechanisms clinically intuitive.
Bisphosphonates protect osteocytes from apoptosis via connexin 43 hemichannels, not just osteoclasts. This is why bisphosphonate holiday in atypical femur fracture is a real concern: suppressing osteocyte-driven remodeling for years impairs damage sensing.
When you see a patient on chronic steroids or with osteonecrosis, the cellular story is osteocyte death: glucocorticoids block FAK/ERK survival signaling in osteocytes, removing the cells that detect microdamage and direct repair. Empty lacunae in osteonecrotic bone are the histologic footprint of this process.
Romosozumab (anti-sclerostin antibody) targets the osteocyte-specific SOST/Wnt axis directly. Its anabolic effect on bone formation is explained by removing sclerostin's brake on LRP5/6 signaling. The same pathway that, when mutated in sclerosteosis, produces pathologically dense bone.
Elevated FGF-23 in your CKD patients is an osteocyte signal gone awry: as kidney disease progresses, osteocyte FGF-23 rises, phosphate handling worsens, and cardiovascular risk climbs. This paper is the conceptual foundation for FGF-23 as a CKD biomarker.
This 2011 narrative review by Bonewald synthesizes a decade of molecular and transgenic evidence redefining the osteocyte as an active orchestrator of bone remodeling and a bona fide endocrine cell. It asks: what do osteocytes actually do, and why does their death matter clinically? The paper covers mechanosensation, sclerostin/Wnt signaling, perilacunar remodeling, phosphate metabolism via FGF-23, and the consequences of osteocyte death.
Two drugs you prescribe regularly — bisphosphonates and romosozumab. Work partly through osteocyte pathways, and understanding this makes their mechanisms clinically intuitive.
Bisphosphonates protect osteocytes from apoptosis via connexin 43 hemichannels, not just osteoclasts. This is why bisphosphonate holiday in atypical femur fracture is a real concern: suppressing osteocyte-driven remodeling for years impairs damage sensing.
When you see a patient on chronic steroids or with osteonecrosis, the cellular story is osteocyte death: glucocorticoids block FAK/ERK survival signaling in osteocytes, removing the cells that detect microdamage and direct repair. Empty lacunae in osteonecrotic bone are the histologic footprint of this process.
Romosozumab (anti-sclerostin antibody) targets the osteocyte-specific SOST/Wnt axis directly. Its anabolic effect on bone formation is explained by removing sclerostin's brake on LRP5/6 signaling. The same pathway that, when mutated in sclerosteosis, produces pathologically dense bone.
Elevated FGF-23 in your CKD patients is an osteocyte signal gone awry: as kidney disease progresses, osteocyte FGF-23 rises, phosphate handling worsens, and cardiovascular risk climbs. This paper is the conceptual foundation for FGF-23 as a CKD biomarker.